Cardiology - Reviews Open access

Long-term colchicine therapy in acute coronary syndromes: a systematic review and meta-analysis of randomized controlled trials

Authors

Published
2 December 2025
Issue
Early Access
Section
Cardiology - Reviews

Abstract

Anti-inflammatory therapy, particularly colchicine, has emerged as a potential secondary prevention strategy post-acute coronary syndrome (ACS). This meta-analysis assessed the impact of long-term colchicine therapy (≥12 months) compared to standard care on cardiovascular events in post-ACS patients. A systematic search of PubMed, Cochrane, Scopus, and Web of Science was conducted on December 22, 2024, for randomized controlled trials (RCTs) comparing long-term (≥12 months) treatment with colchicine to standard care in ACS patients. Outcomes assessed included all-cause mortality, cardiovascular death, myocardial infarction (MI), ischemia-driven revascularization, and stroke. Three RCTs (COLCOT, COPS, and CLEAR SYNERGY) with 12,602 patients were included. Colchicine did not significantly reduce all-cause mortality [hazard ratio (HR) 1.01, 95% confidence interval (CI): 0.67-1.53; I2=54%], cardiovascular death (HR 1.01, 95% CI: 0.80-1.29; I2=0%), or MI (HR 0.86, 95% CI: 0.71-1.05; I2=0%). Ischemia-driven revascularization (HR 0.61, 95% CI: 0.30-1.21; I2=81%) and stroke (HR 0.55, 95% CI: 0.18-1.64; I2=75%) showed non-significant reductions with high heterogeneity. The composite outcome of cardiovascular death, MI, revascularization, or stroke was not significantly reduced (HR 0.80, 95% CI: 0.59-1.07; I2=73%). These findings suggest that long-term colchicine therapy did not confer a consistent reduction in major cardiovascular outcomes after ACS. The pooled results indicate an overall null effect; however, the substantial heterogeneity across trials limits the certainty of this conclusion. This analysis may prompt a reassessment of colchicine’s preventive role in ACS. Future studies should aim to reduce heterogeneity through standardized protocols and follow-up reporting and to explore whether subgroups, such as patients with elevated inflammatory markers, may derive benefit.

References

  1. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015;36:1163-70. DOI: https://doi.org/10.1093/eurheartj/ehu505
  2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New N Engl J Med 2005;352:1685-95. DOI: https://doi.org/10.1056/NEJMra043430
  3. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. DOI: https://doi.org/10.1056/NEJM199704033361401
  4. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. DOI: https://doi.org/10.1056/NEJM200003233421202
  5. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31. DOI: https://doi.org/10.1056/NEJMoa1707914
  6. Leung YY, Yao Hui LL, Kraus VB. Colchicine--update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45:341-50. DOI: https://doi.org/10.1016/j.semarthrit.2015.06.013
  7. Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 2018;269:262-71. DOI: https://doi.org/10.1016/j.atherosclerosis.2017.12.027
  8. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61. Erratum in: Nature 2010;466:652. DOI: https://doi.org/10.1038/nature08938
  9. Nidorf SM, Eikelboom JW, Thompson PL. Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease. J Cardiovasc Pharmacol Ther 2014;19:45-52. DOI: https://doi.org/10.1177/1074248413499972
  10. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45:3415-537. DOI: https://doi.org/10.1093/eurheartj/ehae177
  11. Jolly SS, d'Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. N Engl J Med 2025;392:633-42. DOI: https://doi.org/10.1056/NEJMoa2405922
  12. Fiolet ATL, Poorthuis MHF, Opstal TSJ, et al. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials. eClinicalMedicine 2024;76:102835. DOI: https://doi.org/10.1016/j.eclinm.2024.102835
  13. Shaikh S, Hamza M, Neppala S, et al. Colchicine for secondary prevention in patients with acute coronary syndrome: a systematic review and meta-analysis. Int J Cardiol 2025;425:133045. DOI: https://doi.org/10.1016/j.ijcard.2025.133045
  14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64. DOI: https://doi.org/10.7326/0003-4819-151-4-200908180-00135
  15. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:2497-505. DOI: https://doi.org/10.1056/NEJMoa1912388
  16. Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation 2020;142:1890-900. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.050771
  17. Tong DC, Bloom JE, Quinn S, et al. Colchicine in patients with acute coronary syndrome: two-year follow-up of the Australian COPS randomized clinical trial. Circulation 2021;144:1584-6. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.054610
  18. Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J 2021;42:2765-75. DOI: https://doi.org/10.1093/eurheartj/ehab115
  19. Younas A, Awan Z, Khan T, et al. The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol 2025;50:102878. DOI: https://doi.org/10.1016/j.cpcardiol.2024.102878
  20. Van Broekhoven A, Mohammadnia N, Silvis MJM, et al. End-of-trial inflammatory biomarkers, lipid levels, creatine kinase and markers of renal and liver function in the LoDoCo2 trial. Eur Heart J 2022;43:ehac544.1266. DOI: https://doi.org/10.1093/eurheartj/ehac544.1266
  21. Stewart S, Yang KCK, Atkins K, et al. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 2020;22:28. DOI: https://doi.org/10.1186/s13075-020-2120-7
  22. Hemkens LG, Ewald H, Gloy VL, et al. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart 2016;102:590-6. DOI: https://doi.org/10.1136/heartjnl-2015-308542
  23. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-10. DOI: https://doi.org/10.1016/j.jacc.2012.10.027
  24. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838-47. DOI: https://doi.org/10.1056/NEJMoa2021372

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.